In a subsequent phase II trial (KEYNOT-158, NCT02628067), pembrolizumab treatment was administered in patients with advanced solid tumors without considering PD-L1 status, encompassing 104 patients in the CCA cohort. Here, CD274 is linked to cholangiocarcinoma.